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ication costs were not statistically different between two groups. Factor positively
associated with service costs included excess filler (RR7.9, p0.0002), relapse
event (RR4.0, p0.0001) and adverse event like EPS (RR1.6, p0.008), while types
of antipsychotics and diagnoses were not significant factors after adjusting for
covariates. CONCLUSIONS: SGAs were associated with reduced psychiatric service
uses as compared to FGAs within the 12-month treatment period; however, service
costs were not different and medication costs were significantly higher in the SGAs
group. Excess fillers, relapse and incidence of EPS were factors of high costs among
children and adolescents psychiatric patients treated with antipsychotics in Tai-
wan.
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OBJECTIVES: In developed countries, rotavirus disease causes significant burden,
both on health care systems and society. Two effective and well-tolerated rotavirus
vaccines were marketed in Europe & USA in 2006. Since then, there have been
significant discrepancies in policy decisions and health technology assessments
(HTAs) relating to the inclusion of universal vaccination into national immunisa-
tion programmes, thereby causing unequal population access to rotavirus vacci-
nation. This study aims to understand past HTAs and policy decisions concerning
the recommendation, funding and implementation of universal rotavirus vaccina-
tion in developed countries. METHODS: A comprehensive literature search and
critical appraisal of rotavirus HTAs, statements and policy decisions was per-
formed in 20 developed countries (17 Western European countries, USA, Canada
and Australia). RESULTS: Rotavirus HTAs/statements have been issued in 15 out of
20 countries included in this study. At mid-June 2012, 8 countries have imple-
mented rotavirus vaccination programmes; 2 countries have not recommended
vaccination; 2 countries have recommended and funding processes are ongoing. In
all other countries, the rotavirus decision-making process has not started or is
underway. Despite significant differences in HTA criteria, methods and processes
across countries, there is consistency in the key parameters impacting policy de-
cisions: burden of disease, economic evaluation, vaccine efficacy and safety. Posi-
tive or negative outcomes largely depend on varying interpretations of similar
evidence. For example, several National Immunisation Technical Advisory Groups
and policy makers considered evidence pertaining to rotavirus disease burden
(morbidity) as significant enough to justify its inclusion in the national immunisa-
tion programme, whereas others considered it as insufficient since rotavirus mor-
tality is low. CONCLUSIONS: This study highlights the need for a common decision
analytic framework to foster structured and transparent HTAs and improved de-
cision-making processes, with the ultimate aim of enhancing future European pop-
ulation access to rotavirus vaccination.
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OBJECTIVES: Five years ago the United States government passed the Food and
Drug Administration Amendments Act of 2007 (FDAAA) expanding the FDA’s au-
thority to require post-marketing studies. Prior to this, pregnancy registries, a valu-
able tool for studying the teratogenicity of newly marketed drugs, were primarily
voluntary efforts. Both the FDA (2002) and EMA (2005) issued guidance on post-
marketing studies during pregnancy. The objectives of this research were to eval-
uate the impact of FDAAA on childbearing populations and trends in post-market-
ing commitments/requirements (PMC/Rs). METHODS: Publicly available FDA
databases were analyzed to identify all new molecular entities approved between
January 2008 and May 2012 and associated PMC/Rs and REMS related to pregnancy/
lactation in humans. Data was augmented from the FDA’s list of pregnancy regis-
tries and assigned pregnancy drug category. RESULTS:Over the 4.5 year period, the
FDA approved 125 new compounds (100 drugs, 25 biologics). Overall 78% had at
least one PMC/R (79% of drugs, 84% of biologics). The proportion of new drugs with
a pregnancy related PMC/R was 9% overall and increased over time from 5% in 2008
to a peak of 19% in 2010 before declining to 4% in 2011. Pregnancy categories were
B (26), C (70), D (17), X (12). Of the 57 pregnancy registries listed on the FDA’s website,
13 are associated with drugs approved during the time period under study however
only 6 of these were PMC/R and all were for category C compounds. A single cate-
gory X drug had a pregnancy/lactation related PMC/R.CONCLUSIONS:The majority
of pregnancy registries are for medicines with FDA assigned pregnancy category C.
Category X drugs are not more likely to have REMS or PMC/Rs despite their known
potential for reproductive harm. Population characteristics such as gender, age,
and indication for the prescription are powerful indicators of when PMC/Rs are
necessary.
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OBJECTIVES: Pediatric Investigation Plans (PIPs) were introduced by the European
Commission in January 2007 to help ensure that medicines for children are in-
cluded in the mainstream drug development process in Europe. The objective of
this study was to review all authorized products by the European Medicines Agency
(EMA) from 1995 to 2011 to identify (1) products with a potential pediatric indica-
tion, and (2) products with a PIP application. METHODS: On the EMA website, the
European Public Assessment Reports (EPARs) were searched manually. For each
product, the Summary of Product Characteristics (SmPC) was reviewed to explore
quotes relative to any potential pediatric indication. The products were distributed
in four categories: C1adult indication only; C2safety/efficacy not studied in chil-
dren; C3adult and pediatric indication; and C4pediatric indication only. For
each product, the EMA pediatrics database was searched for PIP applications.
RESULTS:A total of 633 products were authorized by the EMA (281 in 1995-2006 and
352 in 2007-2011). From 1995 to 2006, 33.53% of the authorized products presented
a lack of evidence in the pediatric population as did 57% in the period of 2007-2011.
In total, 746 PIP applications were identified (products authorized and under devel-
opment). A PIP was requested for 21.4% of the products authorized before the
regulation (1995-2006) and for 19% of the products authorized after the EU pediatric
regulation. CONCLUSIONS: The categorization of authorized products according to
the SmPC quotes showed that many products had potential pediatric indications
needing confirmation through new research programs. As expected, most of the
PIP applications concern products under development. However, it is interesting to
note that 20% of the requests concern authorized products, with a higher percent-
age of requests for products authorized before the regulation. These findings sug-
gest that the pediatric regulation in Europe is fostering research to create more
therapeutic options for children.
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OBJECTIVES: There is a lack of long-term data from the real-life setting to docu-
ment the clinical evolution of Alzheimer’s disease (AD) patients, especially in mod-
erate AD where disease management becomes more complex. The EVOCOST study
aims to describe how moderate AD is associated with a relevant disease-related
disability progression and an increase in caregiver burden. METHODS: The EVO-
COST study is a prospective 12-month multicentre cohort study recruiting com-
munity-dwelling moderate AD patients in Spain. Visits were scheduled at baseline,
6 and 12 months according to routine clinical practice. Data on socio-demographic
characteristics, disease history and comorbidities were collected at baseline. Clin-
ical evolution and caregiver burden were measured using the following assess-
ment tools: Global Deterioration Scale (GDS) for severity, Mini-Mental State Exam-
ination (MMSE) for cognition, Clinical Global Impression (CGI) for global status,
Basic and Instrumental Activities of Daily Living (BADL and IADL) for functional
disability, brief Neuropsychiatric Inventory (NPI-Q) for behaviour, Zarit Burden In-
terview (ZBI) and time spent on care for caregiver burden. Changes from baseline
were calculated and tested with Wilcoxon signed rank tests. RESULTS: A total of
209 patients were included at baseline, 76.1% of them were women, with a mean
age of 78.4 years and a mean MMSE of 15.2. At the 12-month visit, data were
available on 174 patients (patient’s attrition rate 16.8%). Clinical symptoms wors-
ened significantly during the 12-month study follow-up in terms of severity
(	GDS0.5, p0.001), cognition (	MMSE-2.9, p0.001), global status
(	CGI0.3, p0.001), and function (	BADL-1.7, p0.001; 	IADL-1.2, p0.001).
No significant change was observed on behaviour (	NPI severity0.5, p0.325;
	NPI distress0.4, p0.375). Caregiver burden also worsened significantly
(	ZBI2.5, p0.002; 	time spent on care56hours per month, p0.001).
CONCLUSIONS: The EVOCOST study illustrates well the patient clinical worsening
and the increase in caregiver’s burden associated with management of moderate
AD.
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OBJECTIVES: To assess clinical effectiveness of cognitive behavioural therapy
(CBT) in patients with multiple sclerosis (MS) fatigue. METHODS: Embase® and
Cochrane databases were searched up to June 2012 to identify randomised con-
trolled trials published in English evaluating effect of CBT (disseminated by any
mode) in patients with MS fatigue. Eligibility of trials was assessed by two review-
ers with any discrepancy reconciled by a third, independent reviewer. To compare
CBT with other therapies, random-effect meta-analysis was conducted using
Stata® (v11.1) on change from baseline to endpoint in fatigue score. RESULTS: Four
studies of 107 retrieved citations met pre-defined inclusion criteria. Two studies
compared CBT to no therapy and one study each compared CBT to relaxation
therapy (RT) and supportive-expressive group therapy (SEGP). All studies were well
conducted and no significant differences were observed between treatment groups
for demographic characteristics. Weighted mean difference (WMD) demonstrated
statistically significant reduction for change in fatigue score at 2 months from
baseline with CBT versus no therapy (-7.04; p0.001). When CBT was compared to
RT, WMD was -4.29 (p0.001) at 2 months, -2.74 (p0.013) at 5 months, and -2.74
(p0.027) at 8 months indicating that CBT group improved significantly on fatigue
than RT group and this improvement was sustained over a period of time. Further,
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